Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 48Plasma cell 38Other hematologic neoplasm 34Myeloid 12Sarcoma 6CNS 5Gastrointestinal 3Dermatologic 2Other solid neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Head and Neck Neoplasms 1

Interventions

Cisplatin 619pembrolizumab 323Radiotherapy 319Cetuximab 274Docetaxel 220Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 74Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 48Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 43tislelizumab 42Standard of Care 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × plerixafor × Head & Neck × Clear all
NCT04058145 2020-09-07

AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

Massachusetts General Hospital

Phase 2 Withdrawn
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡